Updated from 9:10 a.m. ESTTwo pharmaceuticals firms that have lately been distracted from their primary mission of selling drugs posted generally solid earnings Thursday. That could be where the similarities between them end, though. American Home Products ( AHP), which recently resolved litigation over its diet drugs, posted improved net income for the quarter and year based on strong prescription drug sales. The company also said it was on track for double-digit earnings and revenue gains in 2002. Schering-Plough ( SGP), on the other hand, has yet to resolve expensive regulatory problems involving its manufacturing plants. Excluding a $500 million charge to cover potential government fines for the manufacturing issues, the company reported a drop in net income for the quarter and year. And while Schering is looking for earnings growth in the "low double digits" in 2002, it said that will depend on the launch of approved drug Clarinex and reaching a consent decree with the Food and Drug Administration. Late in Thursday's session, American Home was trading down 29 cents, or 0.5%, at $64.20, while Schering-Plough was down 36 cents, or 1%, at $33.50.